Low PSA May Not Fully Predict Survival in Prostate Cancer

Published Date: 14 May 2026

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Read Full News

Latest News

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Todays Updates

Vistagen's Anxiety Disorder Drug Misses Main Goal in Late-stage Trial, Shares Plummet

Vistagen Therapeutics said on Tuesday its experimental anxiety disorder drug failed to meet the main goal of a late-stage ⁠trial testing its ability to reduce symptoms in...

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Todays Updates

Vistagen's Anxiety Disorder Drug Misses Main Goal in Late-stage Trial, Shares Plummet

Vistagen Therapeutics said on Tuesday its experimental anxiety disorder drug failed to meet the main goal of a late-stage ⁠trial testing its ability to reduce symptoms in...

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Latest News

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

News All Time

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Recommended News For You

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Fitness levels for the heart and lungs are linked to a lower mortality from cancer in men.

examining differences in the rates of breast reconstruction following mastectomies.

Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Breast cancer prevention: How nurse practitioners and physician assistants can help

Recommended Articles For You

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction 

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment 

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role 

The New Era of Oncology: Key Updates and Clinical Insights 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

2.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

3.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

4.

How cancer misinformation exploits the way we think

5.

Making informed decisions and managing regret after prostate cancer treatment

1.

A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments

2.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

3.

The Future of Hematology: Innovations Every Doctor Should Know

4.

Know About Lymphangioma: Symptoms, Causes, and Treatments

5.

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

4.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

5.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot